Genetic Polymorphisms of CYP2D6: Prevalence in Healthy Kurds

Q4 Pharmacology, Toxicology and Pharmaceutics

Current Pharmacogenomics and Personalized Medicine Pub Date : 2020-03-31 DOI:10.2174/1875692117666190416145331

M. Ibrahim, Zalina Zahari, Nurfadhlina Musa, K. Yin

{"title":"Genetic Polymorphisms of CYP2D6: Prevalence in Healthy Kurds","authors":"M. Ibrahim, Zalina Zahari, Nurfadhlina Musa, K. Yin","doi":"10.2174/1875692117666190416145331","DOIUrl":null,"url":null,"abstract":"\n\nIdentifying the genetic polymorphisms of drug metabolizing enzyme\nCYP2D6 is useful in pharmacogenomics. Unfortunately, until today, the prevalence\nof the CYP2D6 polymorphisms among Kurds is scarce.\n\n\n\nIn this study, we explored the CYP2D6 polymorphisms among Kurds.\n\n\n\nFour hundred and fifty-nine unrelated healthy Kurds were recruited for the\nstudy. DNA was extracted from whole blood and was then used for genotyping\nCYP2D6*3, *4, *5, *6, *9, *10, *17, *114 and gene duplication using the nested allelespecific\nmultiplex Polymerase Chain Reaction (PCR).\n\n\n\nThe data add to our knowledge of CYP2D6 alleles, the genotypes and the\ndistributions of predicted phenotypes in Kurds. Majority of the observed variant alleles\nconfer no function and gene duplication. CYP2D6 polymorphisms were found to be very\nheterogeneous in relation to genotype frequencies. Further study in relation to the evaluation\nof drug therapy adjustment based on CYP2D6 genotype may help to understand the\nclinical consequences of CYP2D6 polymorphisms.\n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"38 1","pages":"40-47"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692117666190416145331","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Identifying the genetic polymorphisms of drug metabolizing enzyme CYP2D6 is useful in pharmacogenomics. Unfortunately, until today, the prevalence of the CYP2D6 polymorphisms among Kurds is scarce. In this study, we explored the CYP2D6 polymorphisms among Kurds. Four hundred and fifty-nine unrelated healthy Kurds were recruited for the study. DNA was extracted from whole blood and was then used for genotyping CYP2D6*3, *4, *5, *6, *9, *10, *17, *114 and gene duplication using the nested allelespecific multiplex Polymerase Chain Reaction (PCR). The data add to our knowledge of CYP2D6 alleles, the genotypes and the distributions of predicted phenotypes in Kurds. Majority of the observed variant alleles confer no function and gene duplication. CYP2D6 polymorphisms were found to be very heterogeneous in relation to genotype frequencies. Further study in relation to the evaluation of drug therapy adjustment based on CYP2D6 genotype may help to understand the clinical consequences of CYP2D6 polymorphisms.

查看原文本刊更多论文

CYP2D6基因多态性:在健康库尔德人中流行

确定药物代谢酶mecyp2d6的遗传多态性在药物基因组学中是有用的。不幸的是，直到今天，CYP2D6多态性在库尔德人中的患病率还是很低的。在这项研究中，我们探索了库尔德人CYP2D6的多态性。这项研究招募了459名没有血缘关系的健康库尔德人。提取全血DNA，采用巢式等位基因特异性多重聚合酶链反应(PCR)对cyp2d6 *3、*4、*5、*6、*9、*10、*17、*114进行基因分型和基因复制。这些数据增加了我们对库尔德人CYP2D6等位基因、基因型和预测表型分布的了解。大多数观察到的变异等位基因不赋予任何功能和基因复制。发现CYP2D6多态性在基因型频率方面具有很大的异质性。进一步研究基于CYP2D6基因型的药物治疗调整评估，可能有助于了解CYP2D6多态性的临床后果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Pharmacogenomics and Personalized Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.